Arno Amann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6873450/publications.pdf

Version: 2024-02-01

840776 839539 21 392 11 18 citations h-index g-index papers 21 21 21 800 citing authors all docs docs citations times ranked

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open, 2020, 5, e000682. | 4.5 | 64 |
| 2 | Development of a 3D angiogenesis model to study tumour $\hat{a}\in$ endothelial cell interactions and the effects of anti-angiogenic drugs. Scientific Reports, 2017, 7, 2963. | 3.3 | 57 |
| 3 | Neoadjuvant chemo-immunotherapy modifies CD4+CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients. Lung Cancer, 2014, 85, 81-87. | 2.0 | 44 |
| 4 | Evaluation of assays for drug efficacy in a three-dimensional model of the lung. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1955-1966. | 2.5 | 36 |
| 5 | Characterization of DLK1 (PREF1) + I CD34 + cells in vascular stroma of human white adipose tissue. Stem Cell Research, 2015, 15, 403-418. | 0.7 | 30 |
| 6 | The impact of metformin and salinomycin on transforming growth factor \hat{l}^2 -induced epithelial-to-mesenchymal transition in non-small cell lung cancer cell lines. Oncology Letters, 2016, 11, 2946-2952. | 1.8 | 24 |
| 7 | Frequency and risk factors for major complications after stereotactic radiofrequency ablation of liver tumors in 1235 ablation sessions: a 15-year experience. European Radiology, 2021, 31, 3042-3052. | 4.5 | 23 |
| 8 | High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC). Translational Lung Cancer Research, 2021, 10, 304-313. | 2.8 | 23 |
| 9 | Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project. Genes and Cancer, 2016, 7, 301-308. | 1.9 | 15 |
| 10 | The influence of stromal cells and tumor-microenvironment-derived cytokines and chemokines on CD3 ⁺ CD8 ⁺ tumor infiltrating lymphocyte subpopulations. Oncolmmunology, 2017, 6, e1323617. | 4.6 | 14 |
| 11 | Stereotactic radiofrequency ablation (SRFA) for recurrent colorectal liver metastases after hepatic resection. European Journal of Surgical Oncology, 2021, 47, 866-873. | 1.0 | 13 |
| 12 | 3D-cultivation of NSCLC cell lines induce gene expression alterations of key cancer-associated pathways and mimic <i>in-vivo</i> conditions. Oncotarget, 2017, 8, 112647-112661. | 1.8 | 13 |
| 13 | Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition. Lung Cancer, 2021, 159, 84-95. | 2.0 | 12 |
| 14 | Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy. Cancer Biology and Therapy, 2014, 15, 266-270. | 3.4 | 8 |
| 15 | Infiltration of lymphocyte subpopulations into cancer microtissues as a tool for the exploration of immunomodulatory agents and biomarkers. Immunobiology, 2016, 221, 604-617. | 1.9 | 7 |
| 16 | Stereotactic radiofrequency ablation of tumors at the hepatic venous confluence. Hpb, 2022, 24, 1044-1054. | 0.3 | 5 |
| 17 | Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells. Oncology Letters, 2017, 14, 5563-5568. | 1.8 | 3 |
| 18 | Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110399. | 3.2 | 1 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Sorafenib in thyroid cancer—a retrospective case series. Memo - Magazine of European Medical Oncology, 2012, 5, 246-249. | 0.5 | 0 |
| 20 | Rectal cancer: latest developments and innovative new treatment concepts. Memo - Magazine of European Medical Oncology, 2020, 13, 251-252. | 0.5 | 0 |
| 21 | LM02-trial perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases Journal of Clinical Oncology, 2020, 38, e16046-e16046. | 1.6 | 0 |